DrugCite
Search

TIPRANAVIR AND RITONAVIR CO ADMIN

Adverse Events
Drug Profile
Learn More
Reference
About Results
Comments

Tipranavir And Ritonavir Co Admin Adverse Events Reported to the FDA Over Time

How are Tipranavir And Ritonavir Co Admin adverse event reports trending over time?

This graph shows volume of adverse events submitted to the FDA by quarter for Tipranavir And Ritonavir Co Admin, as well as related generic and/or brandname drugs containing the same primary active ingredients. Adverse events are counted if Tipranavir And Ritonavir Co Admin is flagged as the suspect drug causing the adverse event.

Most Common Tipranavir And Ritonavir Co Admin Adverse Events Reported to the FDA

What are the most common Tipranavir And Ritonavir Co Admin adverse events reported to the FDA?

Weight Decreased
18 (2.8%)
Drug Ineffective
17 (2.65%)
Death
16 (2.49%)
Cytolytic Hepatitis
14 (2.18%)
Headache
13 (2.02%)
Nausea
13 (2.02%)
Pyrexia
12 (1.87%)
Caesarean Section
11 (1.71%)
Diarrhoea
9 (1.4%)
Intracranial Pressure Increased
9 (1.4%)
Opisthotonus
9 (1.4%)
Show More Show More
Premature Rupture Of Membranes
9 (1.4%)
Cholestasis
8 (1.25%)
Cough
8 (1.25%)
Pneumonia
8 (1.25%)
Respiratory Arrest
8 (1.25%)
Lung Disorder
7 (1.09%)
Premature Baby
7 (1.09%)
Angina Unstable
6 (.93%)
Drug Exposure During Pregnancy
6 (.93%)
General Physical Health Deteriorati...
6 (.93%)
Hepatic Steatosis
6 (.93%)
Hypertriglyceridaemia
6 (.93%)
Lipodystrophy Acquired
6 (.93%)
Brain Oedema
5 (.78%)
Cachexia
5 (.78%)
Cloacal Exstrophy
5 (.78%)
Depression
5 (.78%)
Drug Abuser
5 (.78%)
Drug Toxicity
5 (.78%)
End Stage Aids
5 (.78%)
Exomphalos
5 (.78%)
Gastrointestinal Disorder Congenita...
5 (.78%)
Genitalia External Ambiguous
5 (.78%)
Hepatitis
5 (.78%)
Hepatitis Cholestatic
5 (.78%)
Liver Disorder
5 (.78%)
Meconium Stain
5 (.78%)
Vomiting
5 (.78%)
Anal Cancer
4 (.62%)
Asthenia
4 (.62%)
Blood Triglycerides Increased
4 (.62%)
Caudal Regression Syndrome
4 (.62%)
Condition Aggravated
4 (.62%)
Congenital Musculoskeletal Anomaly
4 (.62%)
Drug Interaction
4 (.62%)
Gastrointestinal Haemorrhage
4 (.62%)
Haemoglobin Decreased
4 (.62%)
Haemolytic Uraemic Syndrome
4 (.62%)
Meningomyelocele
4 (.62%)
Oesophageal Candidiasis
4 (.62%)
Premature Labour
4 (.62%)
Retinal Detachment
4 (.62%)
Thrombotic Thrombocytopenic Purpura
4 (.62%)
Viral Load
4 (.62%)
Viral Mutation Identified
4 (.62%)
Acne
3 (.47%)
Alanine Aminotransferase Increased
3 (.47%)
Anal Abscess
3 (.47%)
Angina Pectoris
3 (.47%)
Blood Hiv Rna Increased
3 (.47%)
Blood Iron Decreased
3 (.47%)
Cardio-respiratory Arrest
3 (.47%)
Cellulitis
3 (.47%)
Chronic Sinusitis
3 (.47%)
Cytomegalovirus Chorioretinitis
3 (.47%)
Diverticulitis
3 (.47%)
Drug Resistance
3 (.47%)
Enterocolitis
3 (.47%)
Fatigue
3 (.47%)
Gallbladder Polyp
3 (.47%)
Hepatotoxicity
3 (.47%)
Immune Reconstitution Syndrome
3 (.47%)
Lichenoid Keratosis
3 (.47%)
Methaemoglobinaemia
3 (.47%)
Neuropathy Peripheral
3 (.47%)
Optic Atrophy
3 (.47%)
Pancytopenia
3 (.47%)
Pneumonia Pneumococcal
3 (.47%)
Psychotic Disorder
3 (.47%)
Skin Reaction
3 (.47%)
Umbilical Cord Abnormality
3 (.47%)
Abdominal Pain
2 (.31%)
Akinesia
2 (.31%)
Anaemia
2 (.31%)
Aortic Aneurysm
2 (.31%)
Appendicitis Perforated
2 (.31%)
Arrhythmia
2 (.31%)
Aspartate Aminotransferase Increase...
2 (.31%)
Asthma
2 (.31%)
Atrial Fibrillation
2 (.31%)
Bacterial Sepsis
2 (.31%)
Bile Duct Stone
2 (.31%)
Blindness Unilateral
2 (.31%)
Campylobacter Intestinal Infection
2 (.31%)
Chills
2 (.31%)
Cholecystitis
2 (.31%)
Clostridium Colitis
2 (.31%)
Confusional State
2 (.31%)
Cyanosis
2 (.31%)
Cystitis
2 (.31%)

ExportShare/Embed GraphExport Export Data

This graph shows the top adverse events submitted to the FDA for Tipranavir And Ritonavir Co Admin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Tipranavir And Ritonavir Co Admin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Adverse Event Categories for Tipranavir And Ritonavir Co Admin

What are the most common Tipranavir And Ritonavir Co Admin adverse events reported to the FDA?

Show More Show More

ExportShare/Embed Graph Export Export Data

This graph shows the top categories of adverse events submitted to the FDA for Tipranavir And Ritonavir Co Admin, as well as related generic and/or brandname drugs containing the same primary active ingredients, from Q1 2004 to Q3 2012. Adverse events are counted if Tipranavir And Ritonavir Co Admin is flagged as a suspect drug causing the adverse event. For each adverse event listed, percent (%) represents percentage of the adverse event to all adverse events reported for the drug. Percent does not represent a rate related to drug utilization.

Common Uses of Tipranavir And Ritonavir Co Admin According to Those Reporting Adverse Events

Why are people taking Tipranavir And Ritonavir Co Admin, according to those reporting adverse events to the FDA?

Hiv Infection
166
Hiv Test Positive
6
Prophylaxis
6
Human Immunodeficiency Virus Transm...
6
Acquired Immunodeficiency Syndrome
5
Drug Exposure During Pregnancy
2
Show More Show More
Retroviral Infection
2
Drug Level
1

Tipranavir And Ritonavir Co Admin Case Reports

What Tipranavir And Ritonavir Co Admin safety concerns are being reported by doctors and researchers in the medical literature?

Powered by Google

About Results

This report contains aggregated drug side effects and adverse events for Tipranavir And Ritonavir Co Admin. The data has been pulled from the United States Food and Drug Administration's (US FDA) Adverse Event Reporting System (AERS), a database containing more than 4,000,000 adverse event reports.

DrugCite expands your query using the Unified Medical Language System (UMLS) to include generic drugs and primary active ingredients. While the core of DrugCite's advanced drug filtering algorithm is based on the industry standard UMLS, DrugCite's proprietary filtering system also includes dozens of additional steps to reconcile malformed drug names in the FDA's data.

DrugCite only counts a drug if the submitter of the adverse event indicates that the drug is suspected to have caused the adverse event.

Depending on how the data is aggregated, different counts may occur. When someone submits an adverse event to the FDA, the submitter can attribute multiple adverse events to one or more drugs. For example, an individual taking Paxil could submit the adverse events "anxiety" and "suicidal ideation" for the same individual safety report (ISR). This means when DrugCite aggregates by adverse event, two distinct adverse events are counted in the adverse event graph; once for "anxiety" and again for "suicidal ideation". However, when DrugCite aggregates by individual safety reports irrespective of the details of the adverse events contained within the safety report, the report is only counted once.

Comments

Share your experience with Tipranavir And Ritonavir Co Admin.